Topic
Biotechnology
60 stories related to this topic, newest first.
cnbc.comai2 days ago
Hybrid Quantum-Classical System Generates Peptides That Bind Proteins Better Than Classical Model Alone
A Technical University of Denmark team paired a generative AI model with a small quantum computer from ORCA Computing. Laboratory tests showed the hybrid setup produced more successful peptides than classical methods alone, especially with limited training data. The work focused…
wwd.comscience4 days ago
Roche Halts Two Huntington’s Gene-Silencing Drug Programs
Roche stopped development of two Huntington’s disease treatments after new data did not support further testing. ARPA-H separately announced a $160 million program for custom gene-editing therapies for rare diseases.
finance.yahoo.comworld4 days ago
Argent BioPharma Shares Rise 206 Percent After Licensing Deal
Argent BioPharma agreed to license its CannEpil epilepsy drug to Splash Beverage Group in exchange for debt forgiveness. The Sydney Morning Herald reported the transaction removes a US$5.5 million convertible-note liability while retaining royalty rights for Argent.
wwd.comscience4 days ago
Prime Medicine Wins Arbitration Against Beam Therapeutics Over Gene-Editing Agreement
An arbitrator ruled that Prime Medicine's work on an AATD drug did not violate a 2019 agreement with Beam Therapeutics. The decision clears the way for Prime to begin a clinical trial this quarter.
wwd.comscience4 days agoUpdated
ARPA-H to Fund Up to $160 Million for Experimental Gene-Editing Treatments for Rare Diseases
The U.S. health research agency will fund seven teams to develop personalized gene editing therapies for rare diseases. The effort sets a three-year deadline for starting clinical trials.
theverge.comai11 days ago
Anthropic Launches AI Tool for Scientists and Says It Will Develop Drugs for Neglected Diseases
Anthropic introduced Claude Science at an AI for science event this week. The company also said it will develop its own drugs targeting neglected diseases while expanding life sciences hiring.
/cloudfront-us-east-1.images.arcpublishing.com/tgam/KK6TECAC75AUVNR3WA2MYWAQ3M.jpg)
theglobeandmail.comscience11 days ago
Study Finds N4-Acetylcytidine Matches Inflammation Control of N1-Methylpseudouridine While Increasing Protein Output in mRNA Tests
A Nature study finds ac4C-modified mRNA matches m1Ψ in reducing inflammation while producing more protein across cell and animal models. Slower elongation with the current standard contributed to lower output and more errors.
NA
news.sky.comscience12 days ago
Researchers Create Synthetic Cell-Like System That Divides and Replicates DNA
A University of Minnesota team built chemically defined liposomes containing DNA plasmids that divide and retain genetic material across generations. The group formed a public benefit corporation to share the technology and is debating whether the system qualifies as alive.
forbes.comscience13 days ago
Eli Lilly Leads $100 Million Round in AI Drug Developer Absci
Eli Lilly participated in a $100 million stock offering for Absci, an AI-focused drug company. The investment targets development of an injectable antibody for hair loss and endometriosis.
science13 days ago
Amylyx and Biogen to Release Biotech Trial Results This Quarter
Stat reported upcoming data from Amylyx's Phase 3 study of avexitide and detailed results from Biogen's mid-stage Alzheimer's trial. The events form part of the publication's third-quarter biotech scorecard.
theverge.comai13 days ago
Anthropic Launches Pre-Clinical Drug Programs for Neglected Diseases and New Claude Science App
The AI company launched Claude Science on June 30 and said it will start its own drug programs. Executives said the effort will give the firm direct experience applying its tools to scientific problems.
theverge.comai13 days ago
Anthropic Releases Claude Science Tool for Lab and Drug Research
Anthropic announced Claude Science on Tuesday to optimize its large language model for scientific laboratories and pharmaceutical operations. The company reported $42 billion in annualized sales and a $965 billion valuation last month.
forbes.comai15 days ago
Investment firm partners with AI company to develop new biotechs
Population Health Partners entered an agreement with Edison Scientific to create new biotechnology companies. The firm previously profited from a bidding war over an obesity drug startup.
forbes.comworld15 days ago
Japanese Startup to Begin Pig Kidney Transplant Trials at Two Hospitals in 2028
PorMedTec announced plans to begin clinical trials of pig-to-human kidney transplants at Hokkaido University Hospital and Shonan Kamakura General Hospital as early as 2028. The effort uses pigs with 69 gene edits supplied by U.S. firm eGenesis. Japan currently has roughly 15,000…
marketwatch.comscience17 days ago
Interior Department Partners With Dallas Biotech Firm to Build Genetic Archive of Endangered Species
The U.S. Department of the Interior announced a partnership on June 25 with Colossal Biosciences to build a genomic and biobanking archive covering every species protected under the Endangered Species Act. The effort targets genetic diversity among more than 2,300 listed species.
etftrends.comscience17 days ago
Base Editing in Human Embryos Avoids Chromosome Damage but Creates Mosaics
@statnews reported on June 26, 2026, that scientists used base editing in early human embryos to examine genes active in initial development stages. The approach avoided prior chromosome damage but produced mosaic embryos.
Statai18 days ago
Biotech executives discuss China competition and AI use at BIO 2026
Executives at the annual BIO conference in San Diego addressed strategies for competing with Chinese biotech firms and improving returns on artificial intelligence investments.
thesouthafrican.comworld19 days ago
Colossal Biosciences and U.S. Fish and Wildlife Service Partner to Biobank All U.S. Endangered Species
Colossal Biosciences announced on June 25 a partnership with the U.S. Fish and Wildlife Service to collect and freeze cell and tissue samples from every species on the U.S. Endangered Species List. The project will create an open-sourced genomic library for conservation and poten…
Statscience19 days ago
U.S. Lawmakers Prepare New Limits on Chinese Biopharma Ties While Easing Domestic Rules
Political leaders are advancing additional restrictions on U.S. pharmaceutical and biotechnology firms' dealings with Chinese companies. Federal health officials are also easing domestic operations for such firms. The developments follow a 2025 law on the issue.
prnewswire.comscience19 days ago
Vaccine Makers at BIO Conference Report Greater Optimism Than a Year Ago
Executives at the BIO international conference in San Diego said they feel more optimistic despite recent federal actions on mRNA contracts and research funding. Health Secretary Robert F. Kennedy Jr. has cancelled major mRNA vaccine contracts and cut government support for vacci…
world20 days ago
Rwanda Submits Biotech Cassava and Potato Varieties for Regulatory Approval
Rwanda has applied for release of its first biotech cassava and potato seed varieties, with approval expected later in 2026. The programme launched in October 2024 targets cassava brown streak disease, potato late blight, fall armyworm and drought. Trial results show improved res…
Statscience21 days ago
New gene-editing startup raises $230 million via reverse merger with troubled cancer-research firm
Serapha Bio launched June 23, 2026, after raising $230 million and completing a reverse merger. The startup will develop a one-time gene-editing therapy for Alpha-1 Antitrypsin Deficiency.
Fortunebusiness21 days ago
Insilico Medicine signs up to $2.5 billion neuroimmune-drug deal with SK Biopharmaceuticals
Insilico Medicine partnered with SK Biopharmaceuticals in a deal exceeding $2.5 billion to develop neuroimmune drugs. Insilico will apply its Pharma.AI platform while SK Biopharmaceuticals manages later development stages. The agreement marks Insilico’s largest Asia-Pacific tie-u…
New York Postfinance21 days ago
LSD Therapy Shows Significant Benefit in Major Depression Phase 3 Trial
Definium Therapeutics reported that a single dose of its LSD-based pill DT120 produced a 13.3-point drop on a standard depression scale after six weeks, compared with 5.2 points for placebo. The effect remained largely intact at 12 weeks.
Statscience21 days agoUpdated
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion
AbbVie will pay $10.9 billion in cash to buy Apogee Therapeutics, a Waltham-based developer of immunology drugs. The deal values Apogee shares at $135.11 each, a roughly 50 percent premium to the prior close.
newatlas.comscience21 days agoUpdated
Definium LSD therapy reduced depression scores in Phase 3 trial
Definium Therapeutics reported that its LSD-based drug DT120 produced larger reductions in depression scores than placebo in a late-stage study. The company said the results move the therapy closer to potential regulatory review.
Statscience22 days ago
FDA Will Reconsider Gene Therapy for Hunter Syndrome After Earlier Rejection
The Food and Drug Administration will review again an experimental gene therapy for mucopolysaccharidosis type II that it rejected four months ago. The move follows recent leadership changes at the agency.
science23 days ago
Drugmakers test compounds to limit muscle loss during weight reduction
Several pharmaceutical companies are developing medicines that aim to preserve lean mass while patients lose fat. Early human data and repurposed compounds are entering mid-stage trials.
winnipegfreepress.comscience23 days ago
EU Lawmakers Approve Easing of Rules on Gene-Edited Crops
Brussels lawmakers gave final approval earlier this week to easing restrictions on plants obtained by new genomic techniques.
thehindu.comscience28 days ago
Human Cell Atlas Consortium Meets in Boston to Advance First Draft
The International Human Cell Atlas Consortium convenes in Boston this week as it prepares to release single-cell maps of major organs later in 2026.
ai29 days ago
Nano Dimension proposes $890 million merger giving Infinite Epigenetics control of Nasdaq listing
Nano Dimension announced plans to acquire Infinite Epigenetics in a deal valued at $890 million. The transaction would combine Nano Dimension's capital and Nasdaq listing with a healthcare AI platform focused on epigenetic testing.
mhealth.jmir.orgpolitics30 days ago
Drug Barzolvolimab Shows Sustained Angioedema Relief in CSU Patients Seven Months After Dosing
Phase 2 data presented at a medical meeting found that barzolvolimab produced rapid and lasting reductions in angioedema for patients with antihistamine-refractory chronic spontaneous urticaria. Improvements began within one week and continued through 52 weeks of treatment, remai…
Substrate placeholder — needs reviewai31 days ago
Cellular Intelligence acquires global rights to Novo Nordisk Parkinson’s cell therapy program
The Boston-based company gained global rights to the STEM-PD therapy one day before hosting a 28-expert symposium on AI and cell-fate engineering in Copenhagen.
JE
news.sky.comai31 days ago
Cambridge firm uses AI to revive failed drugs
A UK company founded in 2021 applies artificial-intelligence models to identify why certain drugs failed clinical trials and to redesign them for renewed testing. The firm has raised US$6.9 million and built a pipeline focused on autoimmune diseases and blood cancers.
NA
Euronewsscience34 days ago
U.S. biotech firm begins first human test of gene therapy for cellular ageing
A Boston-based biotechnology company has started the first clinical trial of a gene therapy intended to reverse cellular ageing. The treatment, called ER-100, targets optic nerve damage and has moved into Phase 1 safety testing.
insidermonkey.compolitics34 days ago
CervoMed Raises $10.5 Million in Private Placement
CervoMed Inc. announced a private placement expected to generate $10.5 million in gross proceeds. The company said the funds will extend its cash runway into the second quarter of 2027 and support efforts to secure a partner for Phase 3 development of neflamapimod in dementia wit…
Wiredscience35 days ago
Life Biosciences Begins Human Trial of Cellular Rejuvenation Drug for Optic Nerve Conditions
A Boston-based company has started dosing adults in the first human study of ER-100, a therapy designed to restore function in optic-nerve cells damaged by glaucoma or NAION. The trial will track safety and side effects in roughly 18 participants over the next year.
prnewswire.comscience36 days ago
GNI Group to Acquire Ayumi Pharmaceutical Holdings for ¥44.8 Billion
GNI Group Co., Ltd. signed an agreement to purchase all shares of Ayumi Pharmaceutical Holdings Co., Ltd. from its current owners. The deal values the target at approximately ¥44.8 billion and is expected to raise the combined company's fiscal 2026 revenue to about ¥65.2 billion.
New Scientistscience37 days ago
Scientists Create Limited Chimeric Mice With One Added Rat Chromosome From Frozen Tissue, Fail With Others
Researchers at the University of Yamanashi transferred a chromosome from a rat frozen for over a year into mouse cells, producing chimeric mice. The team now plans to test the method on elephant tissue and mammoth chromosomes.
world37 days ago
University of Hong Kong Researchers Develop First Soft 3D Hydrogel Semiconductor
Scientists at the University of Hong Kong developed the first soft three-dimensional semiconductor constructed from hydrogel. The material mimics human tissue and interacts with living cells.
MA
nbcnews.comscience39 days ago
FDA Faces Calls to Pause Makary Drug Voucher Program, Reintroduce via Formal Rulemaking
Patient advocates, former agency officials, and industry players want the FDA to halt the drug voucher program and restart it through formal rulemaking.
Nprai39 days ago
Ginkgo Bioworks Automates Biology Lab With AI and Robots, Raising Biosecurity Concerns
The Boston company, founded nearly two decades ago by four MIT graduate students, now runs an autonomous lab that completed more than 30,000 experiments in six months with AI assistance.
finance.yahoo.comscience39 days ago
Revolution Medicines Offers Daraxonrasib via Expanded Access Program After Positive Pancreatic Cancer Trial
Amy Johnston, 35, diagnosed in 2025, awaits results from a clinical trial by end of June 2026 and may pursue daraxonrasib if unsuccessful. The drug nearly doubled survival in trials but faces production and access delays.
winnipegfreepress.comscience40 days ago
Revolution Medicines pancreatic cancer drug advances toward second-line use
Daraxonrasib is positioned to become the standard second-line treatment for pancreatic cancer. Questions remain about its potential use in newly diagnosed patients.
thehindu.comscience40 days ago
Phage-Delivered CRISPR-Cas12 System Developed to Target Shiga Toxin Gene in E. coli
@ScienceMagazine reported on a new precision antimicrobial that combines CRISPR-Cas12 with phage delivery to address Shiga toxin-producing E. coli infections in animals.
SC
insidermonkey.comscience41 days ago
Legend Biotech shares rise over 40 percent after early in vivo CAR-T data
Legend Biotech shares rose more than 40 percent after the company released early clinical data for its in vivo CAR-T therapy targeting Non-Hodgkin’s lymphoma. The stock moved higher while most other biotech shares declined.
benzinga.comscience42 days ago
Eli Lilly Adds Amylin Receptor Agonists to Camurus Collaboration Agreement
Camurus announced on June 1, 2026 that Eli Lilly exercised its option to include amylin receptor agonists in their June 2025 collaboration and license agreement. The move triggers a $5 million payment and extends Lilly's rights to Camurus' FluidCrystal technology.
The Japan Timesworld44 days ago
Australian Lab-Grown Brain Cells Play Doom on Silicon Chip
Researchers at Cortical Labs trained roughly 200,000 living human neurons to control the 1990s video game Doom. The cells, grown from donated blood stem cells, sit on a silicon chip that converts their electrical signals into game inputs.
AF
techjuice.pkworld44 days agoUpdated
Australian Scientists Grow Neurons on Silicon Chip to Play Classic Video Game Doom
@AFP reported that Australian researchers trained lab-grown brain cells on a silicon computer chip to play the 1990s video game Doom.
AF
prnewswire.comscience45 days ago
Galleri Blood Test Shows No Significant Reduction in Advanced Cancers but Cuts Stage 4 Diagnoses by 14% in Large NHS Trial
A multi-cancer early detection blood test did not reduce late-stage diagnoses when added to standard screening. Data were presented at the American Society of Clinical Oncology meeting in Chicago.
koreaherald.comfinance46 days ago
Aptose Biosciences Delays Closing of Hanmi Acquisition to June
Aptose Biosciences said regulatory approvals in South Korea are still pending for its planned acquisition by Hanmi Pharmaceutical. The companies now target closing in June and have received an additional loan advance to continue operations.
Forbesai47 days ago
Biomanufacturing Shift Focuses on Real-Time Sensing and AI Integration
New in-line sensors and continuous AI models allow operators to track metabolites inside bioreactors instead of relying on delayed offline samples. Industry data show batch failure rates of 5% to 10% for biologics, with individual losses reaching tens of millions of dollars. The…
business47 days ago
Australia to Introduce Capital Gains Tax Legislation Thursday
Labor will introduce legislation on Thursday that replaces the 50 percent CGT discount with an inflation-linked reduction. The government is still consulting on possible carve-outs for startups and biotechnology firms. Industry leaders say the unresolved details have already affe…
Statscience48 days ago
Longevity conference in Berkeley draws founders and researchers for health testing
The Vitalist Bay event held May 14 in Berkeley featured blood testing, workshops, and talks on aging. Organizers described the gathering as a shift from movement to industry.
thestreet.comfinance48 days ago
Analysts Initiate Coverage on Three Biotech and Aerospace Stocks
Mizuho, Roth Capital, and an unnamed GE Aerospace analyst started coverage on Century Therapeutics, BioAge Labs, and GE Aerospace with positive ratings and price targets.
Bloombergfinance48 days ago
Kardigan Files for U.S. IPO to Fund Three Late-Stage Cardiovascular Drugs
Kardigan submitted paperwork for a U.S. initial public offering. The filing states the proceeds will support three late-stage drug candidates aimed at the underlying mechanisms of cardiovascular disease.
Fortuneai49 days ago
Former Palantir Executives Launch Perceptic With $12 Million Seed Round
Three ex-Palantir executives unveiled an end-to-end AI platform for drug development and secured $12 million in seed funding led by Accel. The startup says its software is already in paid use at multiple large pharmaceutical companies.
FO
manilatimes.netfinance49 days ago
Akari Therapeutics Stock Falls After 255 Percent Weekly Gain
Akari Therapeutics PLC shares declined on Tuesday following a 255 percent surge late last week. The movement came after the company reported preclinical results for its AKTX-101 asset in KRAS-mutated pancreatic cancer models.
Statai49 days ago
BigHat Biosciences CEO Describes Limits of AI in Antibody Drug Design
Peyton Greenside, CEO of BigHat Biosciences, said AI can generate antibody designs quickly but that downstream testing still requires substantial time and expense. The company, founded in 2019, has completed projects with several large pharmaceutical partners.
Los Angeles Timesscience51 days ago
Biotech Firm Hatches Chicks in Artificial Eggshell System
Colossal Biosciences reported hatching 26 chickens from a 3D-printed lattice that mimics an eggshell. Independent researchers said the structure functions as an artificial eggshell but lacks other egg components.
AB